Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rally
Biotech cancer-treatment developer Iovance Biotherapeutics Inc. (IOVA) on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administration for lifileucel -- a therapy intended to combat advanced melanoma in some cases. Interim Chief Executive Frederick Vogt said in a statement that completing the submission "is a critical step forward in our journey to deliver the first individualized, one-time cell therapy for a solid tumor." He added: "Our preparations for commercialization remain on track to support a launch later this year." Shares rose 13% after hours on Friday.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 24, 2023 19:55 ET (23:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
, 
, 
Copyright ©2023. All rights reserved.